Abdera raises $110M to push targeted radiotherapies where they haven’t gone before
Radiopharmaceutical biotech Abdera has raised $110 million in a Series B to get its first candidate into the clinic and build out its pipeline.
Abdera was born out of a partnership between two Canadian groups — antibody biotech AbCellera and life science venture firm adMare BioInnovations. The groups came together two years ago with an idea for a platform that could build targeting vectors specifically for radiotherapies. “The vast majority of the field up until recently has really been focused on trying to sort of repurpose antibodies that have already been made in oncology or other targeting ligands,” co-founder and SVP of research Adam Judge told Endpoints News.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
